Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis (sIBM)Intervention: Drug: BYM338 (Bimagrumab)Sponsor: Novartis PharmaceuticalsRecruiting - verified March 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials